S529
Clinical – Head & neck
ESTRO 2026
Digital Poster 145
Digital Poster 71 Stereotactic ablative radiotherapy for oligometastatic head and neck cancer patients: a single center experience Donato Pezzulla 1 , Gabriella macchia 1 , Savino Cilla 2 , Carmela Romano 2 , Milena Ferro 1 , Alessia Re 3 , Francesco Deodato 1,4 1 Radiation Oncology Unit, Responsible Research Hospital, Campobasso, Italy. 2 Medical Physics Unit, Responsible Research Hospital, Campobasso, Italy. 3 Radiation Oncology Unit, Department of Advanced Technology, Azienda Unità Sanitaria Locale -IRCCS di Reggio Emilia, Reggio Emilia, Italy. 4 Institute of Radiology, Università Cattolica del Sacro Cuore, Roma, Italy Purpose/Objective: This study reports clinical outcomes of a monocentric cohort of oligometastatic head and neck cancer (HNC) patients treated with stereotactic body radiotherapy (SBRT) or radiosurgery (SRS). Material/Methods: Data on patients undergone SBRT/SRS retreatment between 2013 and 2025 were retrospectively collected and analyzed. Results: 21 patients, carrying out 33 lesions entered the analysis. 91% of patients had good performance status (ECOG 0-1), and the median age was 73 years (range: 45–80). The most common histology was squamous cell carcinoma (71.4%), primarily from oropharynx and oral cavity (both 23.8%). Lesions were mainly in the lung (33.3%) and bone (27.3%), including eight reirradiated sites. Most were treated with 5-fraction SBRT, while 7 received SRS. Lesions were classified as metachronous (39.5%), induced (24.2%), or repeated (18.1%) Oligoprogressions. Response rates included complete response (CR) in 33.3%, partial response (PR) in 33.3%, stable disease (SD) in 30.3%, and progression in 3.1%, with an overall response rate of 66.6% and a clinical benefit rate of 96.9%. At 12 and 24 months, local control rates were 93.8% and 88.9%, distant metastasis-free survival (DMFS) was 88.9% and 83.3%, and overall survival (OS) was 92.3% and 88.9%, respectively. No Grade ≥ 3 toxicities were reported. Mild acute toxicities occurred in 23.8% of patients; late toxicity, mainly Grade 1, was observed in another 23.8%, without overlap between acute and late cases. Conclusion: SBRT/SRS is a safe and effective treatment option in oligometastatic HNC, providing high local control and minimal toxicity. Keywords: Head & neck, SBRT, oligometastases
Remotely Capturing Patient-Reported Outcomes During and Immediately After Head and Neck Radiation Therapy Devin Hindle 1 , Cory Kapser 2 , Shaneel Pathak 2 , Ezra Hahn 1,3 , Philip Wong 1,3 , Ali Hosni 1,3 , Tara Rosewall 1,3 1 Radiation Medicine Program, Princess Margaret Cancer Centre, Toronto, Canada. 2 Zamplo, Zamplo INC., Calgary, Canada. 3 Department of Radiation Oncology, University of Toronto, Toronto, Canada Purpose/Objective: To examine the feasibility of using a mobile phone app to remotely capture patient-reported outcomes (PROs) during and immediately after radiation therapy (RT) for head and neck cancer (HNC). Material/Methods: English-speaking HNC patients receiving RT were invited to participate in a single-centre, longitudinal quality improvement project. Participants were asked to download a HIPAA/PHIPA compliant mobile app onto their personal device. Unsupervised participants used the app to report PRO-CTCAE at baseline, weekly during RT and up to four weeks after RT. Quality of life (QoL) (UW-QoLv4.1) was reported at baseline, at the end of RT and four weeks after RT. Push notifications automatically delivered reminders to complete surveys. The app also collected pre and post patient- centered communication data (PCC-Ca-6), and participant satisfaction. App use metrics were gathered from audit log timestamps. Results: From Mar. to Nov. 2024, 21 HNC patients participated (21% of eligible population). The mean completion rate across all PRO surveys was 74.3%. Mean age was 64 (SD 11; range 34-81) years, 86% were male, 95% preferred to communicate in English and the most common HNC diagnosis was oropharynx (38%). There were no statistically significant demographic differences between those who were: 1) enrolled and compliant (>70% survey completion); 2) enrolled but non-compliant (<70% completion); and 3) approached but declined participation (p>0.36). There were no significant differences between compliance during RT compared to after RT (mean: 75.2% vs. 72.6%; p 0.55). Taste change was the most severe toxicity; 69% of participants reported at least moderate severity between week four of RT and four weeks after RT, peaking one week after RT to 83%. End of RT health- related QoL (HR-QoL) achieved the lowest score across all QoL domains, reported as good or better by 40% of participants. There were no significant differences between pre and post overall PCC-Ca-6 scores (mean: 0.88 vs. 0.83; p 0.15). At the end of the study, participants spent an average of 9 minutes per session
Made with FlippingBook - Share PDF online